Scaling Up Antiretroviral Therapy in Resource-poor Settings

[1]  Hajime Sato,et al.  Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand , 2003, AIDS.

[2]  Max Essex,et al.  Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in Botswana , 2003, Journal of acquired immune deficiency syndromes.

[3]  M. Kazatchkine,et al.  Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12–26 study , 2003, AIDS (London).

[4]  J. Margolick,et al.  Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men , 2003, AIDS.

[5]  E. Hudes,et al.  Dramatic improvement in survival among adult Brazilian AIDS patients , 2003, AIDS.

[6]  E. Delaporte,et al.  Adherence to HAART and its principal determinants in a cohort of Senegalese adults , 2003, AIDS.

[7]  J. Moatti,et al.  Access to antiretroviral treatment and sexual behaviours of HIV‐infected patients aware of their serostatus in Côte d'Ivoire , 2003, AIDS.

[8]  Richard D Moore,et al.  Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource‐limited settings , 2003, AIDS.

[9]  D. Bangsberg,et al.  Adherence is not a barrier to successful antiretroviral therapy in South Africa , 2003, AIDS.

[10]  E. Noulsri,et al.  Low-cost CD4 enumeration in HIV-infected patients in Thailand. , 2003, Asian Pacific Journal of Allergy and Immunology.

[11]  E. Delaporte,et al.  Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal , 2003, AIDS.

[12]  R. Remien,et al.  Universal access to antiretroviral therapy may be the best approach to 'Do no harm' in developing countries: the Brazilian experience. , 2003, AIDS.

[13]  R. Geskus,et al.  Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. , 2003, Ethiopian medical journal.

[14]  M. Drachler,et al.  Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: a cross-sectional study in Southern Brazil. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[15]  P. Weidle,et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.

[16]  F. Liégeois,et al.  The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study , 2002, AIDS.

[17]  M. Lourenço,et al.  Morbidity and survival in advanced AIDS in Rio de Janeiro, Brazil. , 2002, Revista do Instituto de Medicina Tropical de Sao Paulo.

[18]  D. Vlahov,et al.  Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users , 2002, Journal of epidemiology and community health.

[19]  J. Fisher,et al.  First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. , 2002, AIDS.

[20]  G. Janossy,et al.  Affordable CD4+ T cell counts by flow cytometry. II. The use of fixed whole blood in resource-poor settings. , 2001, Journal of immunological methods.

[21]  R. Rodrigues,et al.  Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. , 2001, AIDS patient care and STDs.

[22]  Paul Farmer,et al.  Community-based approaches to HIV treatment in resource-poor settings , 2001, The Lancet.

[23]  R. Gupta,et al.  Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). , 2001, Bulletin of the World Health Organization.